Articles tagged with: Stem Cell Transplant

NewsFlash »

[ by | Jun 12, 2012 9:21 am | Comments Off ]

Multiple Myeloma Patients Have Low Risk Of Heart Problems Following Stem Cell Transplantation –  Results of a recent retrospective analysis show that 1.6 percent of patients with multiple myeloma develop heart problems following treatment with high-dose melphalan (Alkeran) and autologous stem cell transplantation; however, 5.6 percent of amyloidosis patients develop heart problems after the same procedure. Amyloidosis is a blood disorder that results in the abnormal accumulation of proteins in tissues and organs throughout the body.  An estimated 10 percent to 15 percent of myeloma patients also develop symptoms associated with amyloidosis (see related Beacon news). For amyloidosis patients, a melphalan dose of less than 200 mg/m2, pre-existing heart problems, and abnormal protein accumulation in more than three organs were associated with an increased risk of heart problems following treatment. For more information, please see the study in the European Journal of Haematology (abstract).

AZD7762 May Increase The Efficacy Of Certain Chemotherapy Agents Against Myeloma – Results of a preclinical study indicate that the protein AZD7762 may increase the efficacy of alkylating chemotherapy agents, such as Treanda (bendamustine), melphalan (Alkeran), or doxorubicin (Adriamycin). Specifically AZD7762 increased the agents’ ability to kill multiple myeloma cells. However, AZD7762 did not enhance the efficacy of Velcade (bortezomib), which is not an alkylating agent. AZD7762 is a protein that decreases the ability of cells to repair damaged DNA. Based on their findings, the researchers recommended that AZD7762 be further investigated in combination with alkylating agents. For more information, please see the study in Molecular Cancer Therapeutics (abstract).

Anti-CD47 Antibodies May Inhibit The Growth Of Multiple Myeloma Cells – Results of another preclinical study suggest that treatment with an anti-CD47 antibody may slow the growth of myeloma cells. CD47, a protein frequently found on the surface of myeloma cells, prevents immune cells from engulfing and killing myeloma cells. The anti-CD47 antibody, which belongs to a class of drugs called monoclonal antibodies, blocks CD47 and allows immune cells to function properly and to kill myeloma cells. Other monoclonal antibodies that are already in clinical testing for multiple myeloma include elotuzumab, siltuximab, and daratumumab. For more information, please see the study in Leukemia (abstract).

MMRF Teleconference On Highlights From The ASCO Meeting For Patients And Caregivers – On June 14, the Multiple Myeloma Research Foundation (MMRF) will sponsor a teleconference call entitled “Highlights From the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting for Patients and Caregivers.” The call will begin at 1 p.m. Eastern Time and will be led by myeloma experts Dr. Ravi Vij from the Washington University School of Medicine in St. Louis and by Dr. Todd M. Zimmerman from the University of Chicago Medical Center. They will talk about the latest advances in myeloma treatment from the 2012 ASCO Annual Meeting in Chicago. After the talk, they will answer questions from participants. For more information or to register, please see the MMRF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.


[ by | Jun 5, 2012 3:50 pm | Comments Off ]
ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Current Myeloma Treatments

Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago.  However, yesterday was the last day with any multiple myeloma-related sessions.

During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.

The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.

This update covers some of the myeloma-related studies presented during the poster …

Read the full story »


[ by | Jun 2, 2012 11:56 pm | 5 Comments ]
ASCO 2012 Multiple Myeloma Update – Day Two: Education Session

Today was the second day of the American Society of Clinical Oncology (ASCO) annual meeting.  Although the day has not been as busy with myeloma-related presentations as tomorrow and Monday will be, there still were some interesting presentations and discussions.

The Beacon published an update earlier today with news from a morning poster session that featured several presentations related to multiple myeloma (see related Beacon news).

This article covers material from an early-afternoon education session that was titled: "Controversies in Myeloma: Induction, Transplant, and Maintenance."

The education session included three …

Read the full story »


[ by | May 29, 2012 10:12 am | 11 Comments ]
Day Of Rest Between Melphalan And Stem Cell Infusion May Not Be Necessary For Myeloma Patients

Multiple myeloma patients receiving an infusion of their own stem cells either one day or two days after undergoing treatment with high-dose melphalan demonstrate similar clinical outcomes, according to a recent U.S. study.

The study investigators conclude that a day of rest between treatment with melphalan and stem cell infusion appears not to be necessary.  Based on their findings, they recommend that melphalan administration the day before stem cell infusion should be considered as standard of care.

According to Dr. Giampaolo Talamo of the Penn State Hershey Cancer Institute in …

Read the full story »


[ by | May 24, 2012 12:26 pm | 11 Comments ]
Manhattan Tales: The Stem Cell Transplant And Beyond

As you may remember from my previous column, I was admitted to the hospital for my stem cell transplant at the beginning of March (on March 5 to be exact).

I had no initial devastating reaction to the melphalan (Alkeran) that I received on the day of admission or the infusion of my stem cells over the following two days.

While my first 10 to 11 days were certainly not pleasant, they weren’t “off the charts” bad either. For the first week, I was allowed to walk in …

Read the full story »